| Hazard Information | Back Directory | [Uses]
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease[1]. | [in vivo]
Semorinemab (3, 10 and 30 mg/kg; i.p., once weekly for 13 weeks) reduces accumulation of Tau pathology in a transgenic (Tg) mouse model of tauopathy[1]. | Animal Model: | Tg mouse with the expression of human disease-causing tau mutant (TauP301L-Tg) [1] | | Dosage: | 3, 10 and 30 mg/kg | | Administration: | Intraperitoneal injection; 3, 10 and 30 mg/kg, once weekly for 13 weeks | | Result: | Reduced the accumulation of pathological tau, and dose-dependently decreased pTau212/214 and pTau202/205.
|
| [References]
[1] Ayalon G, et al. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Sci Transl Med. 2021 May 12;13(593):eabb2639. DOI:10.1126/scitranslmed.abb2639 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|